368 related articles for article (PubMed ID: 18787470)
1. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
Lin AY; Brophy N; Fisher GA; So S; Biggs C; Yock TI; Levitt L
Cancer; 2005 Jan; 103(1):119-25. PubMed ID: 15565573
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.
Patt YZ; Hassan MM; Lozano RD; Nooka AK; Schnirer II; Zeldis JB; Abbruzzese JL; Brown TD
Cancer; 2005 Feb; 103(4):749-55. PubMed ID: 15660400
[TBL] [Abstract][Full Text] [Related]
4. Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma.
Chuah B; Lim R; Boyer M; Ong AB; Wong SW; Kong HL; Millward M; Clarke S; Goh BC
Acta Oncol; 2007; 46(2):234-8. PubMed ID: 17453375
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
Daliani DD; Papandreou CN; Thall PF; Wang X; Perez C; Oliva R; Pagliaro L; Amato R
Cancer; 2002 Aug; 95(4):758-65. PubMed ID: 12209719
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
Yau T; Chan P; Wong H; Ng KK; Chok SH; Cheung TT; Lam V; Epstein RJ; Fan ST; Poon RT
Oncology; 2007; 72 Suppl 1():67-71. PubMed ID: 18087184
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma.
Ch'ang HJ; Hsu C; Chen CH; Chang YH; Chang JS; Chen LT
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):817-25. PubMed ID: 21277098
[TBL] [Abstract][Full Text] [Related]
10. Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
Cappa FM; Cantarini MC; Magini G; Zambruni A; Bendini C; Santi V; Bernardi M; Trevisani F
Dig Liver Dis; 2005 Apr; 37(4):254-9. PubMed ID: 15788209
[TBL] [Abstract][Full Text] [Related]
11. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H
Clin Cancer Res; 2001 Sep; 7(9):2675-81. PubMed ID: 11555579
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
Figg WD; Dahut W; Duray P; Hamilton M; Tompkins A; Steinberg SM; Jones E; Premkumar A; Linehan WM; Floeter MK; Chen CC; Dixon S; Kohler DR; Krüger EA; Gubish E; Pluda JM; Reed E
Clin Cancer Res; 2001 Jul; 7(7):1888-93. PubMed ID: 11448901
[TBL] [Abstract][Full Text] [Related]
13. Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma.
Uematsu S; Higashi T; Nouso K; Kariyama K; Nakamura S; Suzuki M; Nakatsukasa H; Kobayashi Y; Hanafusa T; Tsuji T; Shiratori Y
J Gastroenterol Hepatol; 2005 Apr; 20(4):583-8. PubMed ID: 15836707
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma.
Shiah HS; Chao Y; Chen LT; Yao TJ; Huang JD; Chang JY; Chen PJ; Chuang TR; Chin YH; Whang-Peng J; Liu TW
Cancer Chemother Pharmacol; 2006 Nov; 58(5):654-64. PubMed ID: 16520988
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer.
Redman BG; Esper P; Pan Q; Dunn RL; Hussain HK; Chenevert T; Brewer GJ; Merajver SD
Clin Cancer Res; 2003 May; 9(5):1666-72. PubMed ID: 12738719
[TBL] [Abstract][Full Text] [Related]
16. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
Shao YY; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
Cancer; 2010 Oct; 116(19):4590-6. PubMed ID: 20572033
[TBL] [Abstract][Full Text] [Related]
17. Serum endostatin predicts tumor vascularity in hepatocellular carcinoma.
Dhar DK; Ono T; Yamanoi A; Soda Y; Yamaguchi E; Rahman MA; Kohno H; Nagasue N
Cancer; 2002 Nov; 95(10):2188-95. PubMed ID: 12412173
[TBL] [Abstract][Full Text] [Related]
18. alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma.
Chen LT; Liu TW; Chao Y; Shiah HS; Chang JY; Juang SH; Chen SC; Chuang TR; Chin YH; Whang-Peng J
Aliment Pharmacol Ther; 2005 Aug; 22(3):217-26. PubMed ID: 16091059
[TBL] [Abstract][Full Text] [Related]
19. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A
Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151
[TBL] [Abstract][Full Text] [Related]
20. Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors.
Hsu C; Chen CN; Chen LT; Wu CY; Hsieh FJ; Cheng AL
Radiology; 2005 May; 235(2):509-16. PubMed ID: 15858091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]